Ezra Bernstein

Ezra Bernstein

Auto-generated profile, based on publicly available information

Ezra Bernstein

David Geffen School of Medicine at UCLA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in JCO Precision Oncology
Verified
Journal Article
Open access
RTRohit Thummalapalli
Rohit Thummalapalli
EBEzra Bernstein
Ezra Bernstein
BHBenjamin Herzberg
Benjamin Herzberg
BLBob T. Li
Bob T. Li
AIAfsheen Iqbal
Afsheen Iqbal
KAKathryn C. Arbour
Kathryn C. Arbour
PURPOSE: With the recent approval of the KRAS G12C inhibitor sotorasib for patients with advanced KRAS G12C-mutant non–small cell lung cancer (NSCLC), there is a new need to identify factors associated with activity and toxicity among patients treated in routine practice. MATERIALS AND METHODS: We conducted a multicenter retrospective study of patients treated with sotorasib outside of clinical trials to identify factors associated with real-world progression free survival (rwPFS), overall survival (OS), and toxicity. RESULTS: Among 105 patients with advanced KRAS G12C-mutant NSCLC treated with sotorasib, treatment led to a 5.3-month median rwPFS, 12.6-month median OS, and 28% real-world response rate. KEAP1 comutations were associated with shorter rwPFS and OS (rwPFS hazard ratio [HR], 3.19; P = .004; OS HR, 4.10; P = .003); no significant differences in rwPFS or OS were observed across TP53 (rwPFS HR, 1.10; P = .731; OS HR, 1.19; P = .631) or STK11 (rwPFS HR, 1.66; P = .098; OS HR, 1.73; P = .168) comutation status. Notably, almost all patients who developed grade 3 or higher treatment-related adverse events (G3+ TRAEs) had previously been treated with anti–PD-(L)1 therapy. Among these patients, anti–PD-(L)1 therapy exposure within 12 weeks of sotorasib was strongly associated with G3+ TRAEs ( P < .001) and TRAE-related sotorasib discontinuation ( P = .014). Twenty-eight percent of patients with recent anti–PD-(L)1 therapy exposure experienced G3+ TRAEs, most commonly hepatotoxicity. CONCLUSION: Among patients treated with sotorasib in routine practice, KEAP1 comutations were associated with resistance and recent anti–PD-(L)1 therapy exposure was associated with toxicity. These observations may help guide use of sotorasib in the clinic and may help inform the next generation of KRAS G12C-targeted clinical trials.


10 May 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EBEzra Bernstein
Ezra Bernstein
Shahar Lev-ariShahar Lev-ari
Shahar Lev-ari
SSShiran Shapira
Shiran Shapira
ALAri Leshno
Ari Leshno
USUdi Sommer
Udi Sommer
NANadir Arber
Nadir Arber
PURPOSE: Cancer is the second leading cause of death globally. However, by implementing evidence-based prevention strategies, 30%-50% of cancers can be detected early with improved outcomes. At the integrated cancer prevention center (ICPC), we aimed to increase early detection by screening for multiple cancers during one visit. METHODS: Self-referred asymptomatic individuals, age 20-80 years, were included prospectively. Clinical, laboratory, and epidemiological data were obtained by multiple specialists, and further testing was obtained based on symptoms, family history, individual risk factors, and abnormalities identified during the visit. Follow-up recommendations and diagnoses were given as appropriate. RESULTS: Between January 1, 2006, and December 31, 2019, 8,618 men and 8,486 women, average age 47.11 ± 11.71 years, were screened. Of 259 cancers detected through the ICPC, 49 (19.8%) were stage 0, 113 (45.6%) stage I, 30 (12.1%) stage II, 25 (10.1%) stage III, and 31(12.5%) stage IV. Seventeen cancers were missed, six of which were within the scope of the ICPC. Compared with the Israeli registry, at the ICPC, less cancers were diagnosed at a metastatic stage for breast (none v 3.7%), lung (6.7% v 11.4%), colon (20.0% v 46.2%), prostate (5.6% v 10.5%), and cervical/uterine (none v 8.5%) cancers. When compared with the average stage of detection in the United States, detection was earlier for breast, lung, prostate, and female reproductive cancers. Patient satisfaction rate was 8.35 ± 1.85 (scale 1-10). CONCLUSION: We present a proof of concept study for a one-stop-shop approach to cancer screening in a multidisciplinary outpatient clinic. We successfully detected cancers at an early stage, which has the potential to reduce morbidity and mortality as well as offer substantial cost savings. [Media: see text]

19 February 2026 in Cancer Control
Verified
Journal Article
Open access
ILIsaac Lee
Isaac Lee
EBEzra Bernstein
Ezra Bernstein
BLBenjamin Lebwohl
Benjamin Lebwohl
ANAlfred I. Neugut
Alfred I. Neugut
Rising rates of early-onset colorectal cancer have been noted worldwide. This commentary addresses possible causes of this trend and opportunities for intervention.

1 January 2019 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
PDF file
ITItai Tzfoni
Itai Tzfoni
JCJennifer Chayo
Jennifer Chayo
MSMeital Shaked
Meital Shaked
EBEzra Bernstein
Ezra Bernstein
RDRoy Dekel
Roy Dekel
SSShiran Shapira
Shiran Shapira
Bloom syndrome is a rare autosomal recessive disorder characterized by distinct physical features, such as short stature, genomic instability, and predisposition to numerous cancers. The BLM gene encodes for the RecQ helicase that plays an important role in genome editing, maintenance, and stability. Mutations in the BLM gene cause genomic instability that exposes the carriers to a variety of cancers, and in particular hematological and gastrointestinal cancers. Herein, we report the first case of pancreatic cancer in a 32-year-old patient with bloom syndrome.

9 April 2017
Verified
Book Chapter
Closed access
PDF file
EBEzra A. Bernstein
Ezra A. Bernstein
YSYvonne Saenger
Yvonne Saenger